Mark E. Bunnage, EVP and Chief Scientific Officer at Vertex Pharmaceuticals ($VRTX), sold shares on the open market four times over the past year, totaling nearly $3 million. His most recent sale occurred on February 25, 2026. These sales rank 2,736th among 11,678 individual insiders in our database, where the average is about $8.6 million across roughly 6.4 transactions per insider. Bunnage made no open market purchases during this period.
| Transaction Date | Company | Ticker | Insider Name | Title | Transaction Type | Security | Shares | Price | Shares Owned Following | Total Shares Outstanding | % of Owned | % of Outstanding |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb. 24, 2026 | VERTEX PHARMACEUTICALS INC / MA | $VRTX | Bunnage Mark E. | EVP, Chief Scientific Officer | F | Common Stock | 582 | $485.11 | 7,904.0000 | 258,000,000 | 6.86% | 0.00% |
| Feb. 25, 2026 | VERTEX PHARMACEUTICALS INC / MA | $VRTX | Bunnage Mark E. | EVP, Chief Scientific Officer | S | Common Stock | 620 | $486.35 | 7,284.0000 | 258,000,000 | 7.84% | 0.00% |
| Feb. 17, 2026 | VERTEX PHARMACEUTICALS INC / MA | $VRTX | Bunnage Mark E. | EVP, Chief Scientific Officer | F | Common Stock | 1110 | $483.75 | 12,105.0000 | 258,000,000 | 8.40% | 0.00% |
| Feb. 17, 2026 | VERTEX PHARMACEUTICALS INC / MA | $VRTX | Bunnage Mark E. | EVP, Chief Scientific Officer | A | Common Stock | 2584 | $0.00 | 13,215.0000 | 258,000,000 | 24.31% | 0.00% |
| Feb. 17, 2026 | VERTEX PHARMACEUTICALS INC / MA | $VRTX | Bunnage Mark E. | EVP, Chief Scientific Officer | S | Common Stock | 2437 | $489.46 | 9,668.0000 | 258,000,000 | 20.13% | 0.00% |
| Feb. 18, 2026 | VERTEX PHARMACEUTICALS INC / MA | $VRTX | Bunnage Mark E. | EVP, Chief Scientific Officer | S | Common Stock | 1182 | $473.68 | 8,486.0000 | 258,000,000 | 12.23% | 0.00% |
| Feb. 13, 2026 | VERTEX PHARMACEUTICALS INC / MA | $VRTX | Bunnage Mark E. | EVP, Chief Scientific Officer | F | Common Stock | 2283 | $487.76 | 10,631.0000 | 258,000,000 | 17.68% | 0.00% |
| Feb. 11, 2026 | VERTEX PHARMACEUTICALS INC / MA | $VRTX | Bunnage Mark E. | EVP, Chief Scientific Officer | S | Common Stock | 2021 | $460.43 | 12,914.0000 | 258,000,000 | 13.53% | 0.00% |
| Feb. 10, 2026 | VERTEX PHARMACEUTICALS INC / MA | $VRTX | Bunnage Mark E. | EVP, Chief Scientific Officer | F | Common Stock | 1127 | $468.41 | 14,935.0000 | 258,000,000 | 7.02% | 0.00% |